查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870141

癌症影像诊断系统市场按产品类型、应用、技术和最终用户划分 - 全球预测 2025-2032

Cancer Imaging System Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症影像诊断系统市场将成长至 428.1 亿美元，复合年增长率为 9.86%。

关键市场统计数据
基准年 2024 201.6亿美元
预计年份：2025年 221.8亿美元
预测年份 2032 428.1亿美元
复合年增长率 (%) 9.86%

针对当前癌症影像领域的关键挑战，本文建构了一个全面的框架，重点阐述了诊断准确性、工作流程整合以及临床领导者应关注的策略投资重点。

现代肿瘤学领域需要兼具诊断准确性和操作效率的影像系统。电脑断层扫描 (CT)、磁振造影(MRI)、混合成像模式以及人工智慧驱动的工作流程的进步正在改变临床医生检测、分期和后续观察恶性肿瘤的方式。放射科团队和医院管理者在评估影像投资时，不仅关注影像质量，也越来越重视互通性、吞吐量、病患舒适度以及对跨学科诊疗路径的后续影响。

观察影像技术的进步、计算能力的增强以及综合护理路径如何重塑肿瘤影像的诊断工作流程和采购理念。

癌症影像领域正经历一场变革，这场变革由三大并行因素驱动：影像技术创新、运算技术和诊疗路径整合。影像技术创新不断提升CT和MRI平台的空间和时间分辨率，而混合系统和检测器技术的进步则缩短了扫描时间，提高了病灶的可见度。同时，包括人工智慧和3D视觉化工具在内的计算技术正在改善病灶检测、实现定量测量的自动化以及规范各医疗机构间的报告流程，从而提高诊断的一致性并加快决策速度。

评估关税主导的采购压力和供应链韧性策略，以重塑诊断影像服务提供者到 2025 年的采购、资金筹措和生命週期规划。

2025年推出的新关税措施正在加强对医疗影像生态系统供应链的审查，促使采购负责人重新评估零件采购、製造地和整体拥有成本的假设。进口影像零件和资本设备的关税给采购预算带来了上行压力，促使采购者重新评估维护策略、延长设备更新周期，并探索能够减轻即时资本负担的替代资金筹措结构。这种财务压力也促使企业更加重视区域製造和在地化供应链网络，以降低跨境贸易政策波动带来的风险。

透过详细的細項分析，将产品类型、临床应用、底层技术和最终用户优先顺序连结起来，以指导模式选择和服务模式设计。

了解细分市场的细微差别对于使产品选择和服务模式与临床和营运目标保持一致至关重要。就产品类型而言，电脑断层扫描 (CT) 产品涵盖范围广泛，从针对高解析度局部影像最佳化的锥状射束CT，到用于提高时间解析度的双源 CT，再到兼顾速度和影像品质的多层螺旋 CT 系统。同时，数位放射线(DR) 选项包括电荷耦合元件 (CCD) 和平板检测器技术，这些技术会影响剂量效率和工作流程整合。多切面磁振造影(MRI) 提供封闭式系统（优先考虑高场成像以提高诊断准确性）、专用于四肢肌肉骨骼成像的超强 MRI 系统以及旨在提高患者舒适度的开放式 MRI 解决方案。正子断层扫描 (PET) 的独特之处在于其 PET-CT 混合系统（整合解剖和代谢数据）以及 PET-MRI 混合系统（将卓越的软组织对比度与分子成像相结合）。超音波透过多普勒分析进行血管评估，透过二维成像进行常规评估，透过三维或四维分析辅助进行体积评估和手术指导，从而继续满足各种临床需求。

医疗保健结构、法规环境和基础设施优先事项的差异，导致了不同地区的采用情况和供应商的打入市场策略的差异。

区域趋势对肿瘤影像领域的普及曲线、供应商策略和服务交付模式有显着影响。在美洲，注重互通性、清晰的报销机制和全生命週期服务协议的综合医疗系统和大型医院网路正在塑造市场需求。製造商通常会与当地服务供应商建立策略联盟，以确保运作并协助完成复杂的混合安装。在欧洲、中东和非洲，不同的法规环境和采购机製造就了不同的普及路径。这些地区通常呈现出一种平衡：一方面是集中式学术机构推动早期普及，另一方面是分散式诊所优先考虑成本效益高的模式和模组化升级。同时，地缘政治因素和基础设施投资的不均衡可能会加速人们对移动式和可扩展影像解决方案的兴趣。

结合卓越的硬体、软体生态系统以及专注于临床检验和营运连续性的服务模式，实现竞争优势。

产业相关人员正透过整合卓越的硬体和软体服务、数据分析以及全面的维护计划来建立差异化优势。在传统成像设备製造商持续投资于检测器技术、磁铁设计和混合成像技术的同时，他们也在加速推进人工智慧演算法和视觉化套件的伙伴关係开发和内部研发，以拓展其价值主张，使其超越单纯的影像生成。同时，越来越多的专业技术公司正专注于人工智慧驱动的检测技术、工作流程编排和云端原生影像管理，这迫使传统供应商扩展其软体和服务组合。

供应商和服务商可采取的策略重点：模组化平台、检验的人工智慧、灵活的采购方式以及增强的本地服务能力

产业领导者若想更能掌握临床需求和政策变化，应采取以下几项相互关联的策略：首先，优先发展模组化产品架构和软体可升级平台，使客户无需更换硬体即可延长系统寿命并引入新的分析功能。其次，投资于经临床检验的人工智慧工具和严谨的多中心研究，以证明其在病灶检测、报告一致性和工作流程效率方面能够带来可衡量的改进，从而消除监管障碍并提高采购方的接受度。

采用透明的混合方法，结合相关人员访谈、临床文献综述和技术比较评估，以产生可操作的影像学见解。

本研究整合了一手和二手讯息，以得出循证见解和实用建议。一级资讯来源包括对临床放射科医生、影像中心主任、采购负责人和设备服务经理的结构化访谈，以了解操作流程、影像设备优先顺序和采购限制。这些定性资讯与技术文献、同行评审的临床研究、与监管机构的沟通以及製造商的产品规格进行交叉核对，以确保与当前的临床证据和设备性能声明保持一致。

总之，综合审查强调了将影像能力与临床路径结合的重要性、务实的采购方法以及已证实的患者获益。

随着癌症治疗中早期检测、精准分期和个人化治疗方案的日益普及，诊断影像系统仍然是多学科肿瘤诊疗流程的核心。先进成像设备、混合成像技术和计算分析的融合正在重塑诊断能力和操作预期。专注于互通性、检验的计算工具和灵活服务模式的医疗机构和供应商，将更有能力将技术进步转化为可衡量的临床效益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人工智慧驱动的影像分析演算法在癌症早期检测和预后预测的应用日益广泛
  • 引进整合PET、CT和MRI的多模态影像平台，用于精准肿瘤学工作流程
  • 携带式和照护现场影像解决方案的发展使得在资源匮乏地区进行远端癌症筛检成为可能；治疗性造影剂的出现将分子诊断与靶向放射治疗计划联繫起来；机器学习模型在临床环境中用于自动肿瘤分割和体积评估的日益普及；前列腺肿瘤和神经内分泌肿瘤
  • 治疗性造影剂的出现将分子诊断与标靶放射治疗计划联繫起来
  • 在临床环境中扩大机器学习模型在肿瘤自动分割和体积评估的应用
  • 一种新型PET示踪剂核准监管部门批准，可增强前列腺癌和神经内分泌肿瘤的检测。
  • 开发一种混合型PET/MRI扫描仪，可提高软组织对比度并降低肿瘤影像诊断中的辐射暴露。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症影像诊断系统市场（依产品类型划分）

  • 电脑断层扫描
    • 锥状射束CT
    • 双源CT
    • 多切面CT
  • 数位放射线
    • 电荷耦合元件
    • 平板检测器
  • 磁振造影
    • 封闭式磁振造影装置
    • 四肢磁振造影
    • 开放式磁振造影装置
  • 正子断层扫描
    • PET CT
    • PET MRI
  • 超音波
    • 多普勒分析
    • 3D/4D 分析
    • 二维分析

第九章 按应用分類的癌症影像诊断系统市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第十章 癌症影像诊断系统市场（依技术划分）

  • 人工智慧
    • 电脑辅助检测
    • 电脑辅助诊断
    • 工作流程管理
  • 使用造影剂进行诊断影像
    • CT造影剂
    • 磁振造影剂
    • 超音波造影剂
  • 混合成像
    • PET-CT混合
    • PET-MRI混合影像
    • SPECT CT 混合
  • 3D可视化
    • 最大强度投影
    • 表面渲染
    • 体绘製

第十一章 癌症影像诊断系统市场（以最终用户划分）

  • 学术研究机构
  • 诊所
  • 诊断影像中心
  • 医院

第十二章 区域癌症影像诊断系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 癌症影像诊断系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国癌症影像诊断系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GE HealthCare Technologies, Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • Fujifilm Holdings Corporation
    • Hitachi, Ltd.
    • Shimadzu Corporation
    • Konica Minolta, Inc.
    • Samsung Medison Co., Ltd.
    • Hologic, Inc.
Product Code: MRR-3204321AF6C5

The Cancer Imaging System Market is projected to grow by USD 42.81 billion at a CAGR of 9.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.16 billion
Estimated Year [2025] USD 22.18 billion
Forecast Year [2032] USD 42.81 billion
CAGR (%) 9.86%

Comprehensive framing of current cancer imaging imperatives emphasizing diagnostic precision, workflow integration, and strategic investment priorities for clinical leaders

The contemporary oncology landscape demands imaging systems that combine diagnostic precision with operational efficiency. Advances across computed tomography, magnetic resonance imaging, hybrid modalities, and AI-driven workflows are changing how clinicians detect, stage, and monitor malignancies. Radiology teams and hospital administrators now evaluate imaging investments not solely on image quality but on interoperability, throughput, patient comfort, and downstream impact on multidisciplinary care pathways.

Clinical adoption is being accelerated by tighter integration between imaging modalities and cloud-enabled data management, while value-based care imperatives drive institutions to quantify diagnostic yield and follow-up reductions. At the same time, regulatory scrutiny and reimbursement dynamics influence procurement timelines and capital planning. Therefore, leaders must synthesize technical performance with clinical workflows and fiscal realities when assessing cancer imaging strategies.

This introduction frames the subsequent analysis by focusing on the interplay between modality innovation, technology convergence, and stakeholder requirements. It underscores the necessity for health systems and diagnostic providers to align selection criteria with long-term clinical objectives and operational resilience, and it sets the stage for deeper examination of industry shifts, policy impacts, segmentation insights, and regional dynamics that shape procurement and adoption decisions.

Observing modality advances, computational augmentation, and care pathway integration reshaping diagnostic workflows and procurement philosophies in oncology imaging

The cancer imaging landscape is undergoing transformative shifts driven by three parallel vectors: modality innovation, computational augmentation, and care pathway integration. Modality innovation continues to refine spatial and temporal resolution across CT and MRI platforms while hybrid systems and advances in detector technology reduce scan times and improve lesion conspicuity. Concurrently, computational augmentation through artificial intelligence and three-dimensional visualization tools enhances lesion detection, automates quantitative measurements, and standardizes reporting across sites, thereby improving diagnostic consistency and enabling accelerated decision-making.

Care pathway integration is aligning imaging outputs with multidisciplinary oncology workflows. Radiology reports increasingly feed structured data into tumor boards, surgical planning, and radiation therapy contouring systems. This integration reduces handoff friction and shortens time-to-treatment for complex cases. Additionally, manufacturers and providers are prioritizing patient-centric features such as open-bore MRI designs and faster CT protocols to improve tolerability and throughput, which in turn impacts scheduling efficiency and downstream revenue cycles.

Finally, procurement and service models are shifting toward outcome-oriented contracts and managed equipment services that bundle uptime guarantees, software updates, and AI tool access. These arrangements reflect a broader industry move away from transactional purchasing and toward partnerships that share operational risk and align vendor incentives with clinical outcomes and system efficiency.

Assessment of tariff-driven procurement pressures and supply chain resilience strategies reshaping sourcing, financing, and lifecycle planning across imaging providers in 2025

The introduction of new tariff measures in 2025 has amplified supply chain scrutiny within the medical imaging ecosystem, prompting procurement leaders to evaluate component sourcing, manufacturing footprints, and total cost of ownership assumptions. Tariffs on imported imaging components and capital equipment have placed upward pressure on procurement budgets, encouraging buyers to revisit maintenance strategies, extend equipment refresh cycles, and explore alternative financing structures that mitigate immediate capital strain. This fiscal pressure has also stimulated wider consideration of regional manufacturing and localized supply networks to reduce exposure to cross-border trade policy volatility.

In response, some vendors have accelerated supplier diversification and nearshoring initiatives, relocating critical supply chain nodes closer to major end markets to limit tariff pass-through and shorten lead times. These strategic shifts, however, require substantial lead-time investments and complex qualification of new suppliers to preserve image quality and device safety. Meanwhile, clinical providers have adapted by emphasizing modular upgrades and software-driven performance enhancements that defer full-platform replacement while still delivering incremental clinical benefits.

Regulatory authorities and reimbursement payers have begun assessing whether tariff-induced cost changes necessitate updates to equipment valuation frameworks and procurement guidelines. Hospitals and imaging centers are increasingly negotiating total lifecycle service agreements and consumables bundling to stabilize operational expenses amid pricing uncertainty. As a result, stakeholders are prioritizing resilient procurement strategies, strengthening vendor partnerships, and integrating scenario-based financial planning to preserve access to advanced imaging capabilities while managing near-term cost impacts.

Granular segmentation insights linking product types, clinical applications, enabling technologies, and end user priorities to inform modality selection and service model design

Understanding segmentation nuances is essential for aligning product selection and service models with clinical and operational objectives. When considering product type, computed tomography offerings range from cone beam CT optimized for high-resolution localized imaging to dual source CT that enhances temporal resolution and multi slice CT systems that balance speed and image quality, while digital radiography options include charged coupled device and flat panel detector technologies that affect dose efficiency and workflow integration. Magnetic resonance imaging is available in closed configurations that prioritize high-field diagnostic clarity, extremity MRI systems that deliver focused musculoskeletal imaging, and open MRI solutions that improve patient comfort. Positron emission tomography remains differentiated by PET CT hybrids that merge anatomical and metabolic data and PET MRI hybrids that combine superior soft-tissue contrast with molecular imaging. Ultrasound continues to serve diverse clinical needs through Doppler analysis for vascular assessment, two-dimensional imaging for routine evaluation, and three-dimensional or four-dimensional analyses that support volumetric assessment and procedural guidance.

Applications drive modality prioritization, with specific clinical use cases such as breast cancer screening and diagnostic workup favoring high-resolution mammographic and hybrid solutions, colorectal cancer surveillance requiring cross-sectional imaging and contrast-enhanced techniques, lung cancer pathways depending heavily on low-dose CT protocols and PET-based metabolic characterization, and prostate cancer management leveraging multiparametric MRI and targeted ultrasound interventions. Technology choices further refine value propositions: artificial intelligence supports computer aided detection, computer aided diagnosis, and workflow management that together improve throughput and diagnostic reliability; contrast imaging modalities rely on CT, MRI, and ultrasound agents to enhance lesion delineation and functional assessment; hybrid imaging configurations such as PET CT, PET MRI, and SPECT CT bring complementary diagnostic dimensions; and three-dimensional visualization techniques including maximum intensity projection, surface rendering, and volume rendering facilitate surgical planning and radiotherapy contouring.

End users present distinct procurement and usage patterns. Academic research institutes prioritize extensibility, advanced analytic capabilities, and study-grade data capture. Clinics and diagnostic imaging centers favor throughput, cost-effectiveness, and integrated reporting that streamlines patient throughput. Hospitals require scalable systems that balance acute care demands with outpatient diagnostic volumes and emphasize serviceability and contract support. Recognizing these segmentation layers enables supply-side and clinical leaders to match modality selection and service models to institutional priorities, ensuring investments support diagnostic yield, operational efficiency, and clinical workflow integration.

Regional adoption contrasts and vendor go-to-market adaptations driven by differing healthcare structures, regulatory environments, and infrastructure priorities

Regional dynamics significantly influence adoption curves, vendor strategies, and service delivery models across the cancer imaging landscape. In the Americas, demand is shaped by integrated health systems and large hospital networks that emphasize interoperability, reimbursement clarity, and lifecycle service agreements; manufacturers often pursue strategic partnerships with regional service providers to ensure uptime and to support complex hybrid installations. Europe, the Middle East & Africa features heterogeneous regulatory environments and procurement mechanisms that create varied adoption pathways; this region commonly balances centralized academic centers driving early adoption with decentralized clinics prioritizing cost-effective modalities and modular upgrades, while geopolitical factors and uneven infrastructure investment can accelerate interest in mobile and scalable imaging solutions.

Asia-Pacific continues to exhibit rapid investment in capacity expansion and technology adoption driven by population-scale screening programs and growing cancer care networks, leading to a diverse landscape where high-volume urban centers adopt cutting-edge hybrid and AI-enabled systems while secondary markets prioritize robust, easy-to-service platforms. Vendors respond by tailoring go-to-market approaches and financing models to regional needs, offering managed service options, training programs, and localized support hubs. These regional contrasts influence product development roadmaps and aftermarket strategies, encouraging vendors to design platforms that balance global technical standards with configurable deployment options for distinct regulatory and clinical contexts.

Competitive differentiation through combined hardware excellence, software ecosystems, and service models that prioritize clinical validation and operational continuity

Industry participants are increasingly differentiating through integrated ecosystems that combine hardware excellence with software services, data analytics, and comprehensive maintenance programs. Established imaging manufacturers continue to invest in detector technologies, magnet design, and hybrid modality engineering while also accelerating partnerships and in-house development of AI algorithms and visualization suites to extend value beyond raw image generation. Concurrently, a growing cohort of specialist technology firms focuses on AI-enabled detection, workflow orchestration, and cloud-native image management, pressuring traditional vendors to broaden their software and service portfolios.

Strategic activity includes partnerships for clinical validation, regulatory submissions for AI tools, and the expansion of service footprints to support complex hybrid installations and bundled consumables. Competitive positioning increasingly depends on demonstrating clinical utility through peer-reviewed evidence and cross-site validation studies that show reproducible improvements in diagnostic accuracy and workflow efficiency. Additionally, vendors that offer flexible financing, comprehensive training, and outcome-linked service agreements gain traction among large health systems seeking to align vendor incentives with clinical performance and operational uptime.

Actionable strategic priorities for vendors and providers focusing on modular platforms, validated AI, flexible procurement, and resilient regional service capabilities

Industry leaders can act decisively to capitalize on clinical demand and policy shifts by pursuing several interlocking strategies. First, prioritize modular product architectures and software-upgradeable platforms that allow customers to extend system life and adopt new analytic capabilities without full hardware replacement. Second, invest in clinically validated AI tools and rigorous multi-center studies that demonstrate measurable improvements in lesion detection, reporting consistency, and workflow efficiency, thereby smoothing regulatory pathways and buyer acceptance.

Third, develop flexible procurement options including managed service agreements, subscription licensing, and outcome-linked contracts that align vendor revenue models with customer operational goals. Fourth, strengthen regional service networks and spare-part ecosystems to mitigate tariff and supply chain risk, and consider nearshoring critical component manufacturing where feasible to stabilize lead times and costs. Fifth, design training and implementation programs that embed imaging outputs into multidisciplinary care pathways, ensuring that new capabilities translate into faster clinical decisions and measurable patient benefit. Executing these priorities will require cross-functional coordination among R&D, regulatory affairs, commercial teams, and clinical partners to deliver cohesive product and service propositions that meet the evolving needs of oncologic care providers.

Transparent mixed-methods approach combining stakeholder interviews, clinical literature review, and comparative technology assessments to produce actionable imaging insights

This research synthesized primary and secondary intelligence to produce evidence-based insights and practical recommendations. Primary inputs included structured interviews with clinical radiologists, imaging center directors, procurement officers, and device service managers to capture operational realities, modality priorities, and procurement constraints. These qualitative inputs were triangulated with technical literature, peer-reviewed clinical studies, regulatory communications, and manufacturer product specifications to ensure alignment with current clinical evidence and device performance claims.

Analytical methods combined thematic analysis of stakeholder interviews with comparative technology assessment frameworks that evaluate image quality, throughput, serviceability, and software integration potential. Supply chain and policy impacts were assessed through scenario planning that considered tariff changes, supplier diversification efforts, and regional manufacturing shifts. Throughout, emphasis remained on verifiable clinical and operational outcomes rather than speculative forecasts, and recommendations were calibrated to align with typical procurement cycles and capital planning horizons across hospital systems and diagnostic providers.

Concluding synthesis emphasizing the necessity of aligning imaging capabilities with clinical pathways, procurement pragmatism, and demonstrated patient benefit

As cancer care increasingly prioritizes early detection, precision staging, and personalized treatment planning, imaging systems will remain central to multidisciplinary oncology pathways. The convergence of advanced modality hardware, hybrid imaging techniques, and computational analytics is reshaping diagnostic capabilities and operational expectations. Providers and vendors who focus on interoperability, validated computational tools, and flexible service models will be best positioned to translate technological advances into measurable clinical gains.

Policy and procurement environments will continue to influence adoption patterns, making supply chain resilience and financing flexibility critical considerations for sustained access to advanced imaging. Ultimately, success will hinge on aligning product capabilities with clinical workflows and outcome metrics, thereby ensuring that investments in imaging technology directly support improved patient pathways and system efficiency. Stakeholders should treat imaging strategy as an integral component of broader oncology program development rather than as an isolated capital decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of AI-driven image analysis algorithms for early cancer detection and prognosis
  • 5.2. Integration of multimodal imaging platforms combining PET, CT and MRI for precision oncology workflows
  • 5.3. Growth in portable and point-of-care imaging solutions enabling remote cancer screening in low resource settings
  • 5.4. Emergence of theranostic imaging agents linking molecular diagnostics with targeted radiotherapy planning
  • 5.5. Increasing use of machine learning models for automated tumor segmentation and volumetric assessment in clinical practice
  • 5.6. Regulatory approvals of novel PET tracers enhancing detection of prostate and neuroendocrine tumors
  • 5.7. Development of hybrid PET/MRI scanners improving soft tissue contrast and reducing radiation exposure in oncologic imaging

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Imaging System Market, by Product Type

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam Computed Tomography
    • 8.1.2. Dual Source Computed Tomography
    • 8.1.3. Multi Slice Computed Tomography
  • 8.2. Digital Radiography
    • 8.2.1. Charged Coupled Device
    • 8.2.2. Flat Panel Detector
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Closed Magnetic Resonance Imaging
    • 8.3.2. Extremity Magnetic Resonance Imaging
    • 8.3.3. Open Magnetic Resonance Imaging
  • 8.4. Positron Emission Tomography
    • 8.4.1. PET CT
    • 8.4.2. PET MRI
  • 8.5. Ultrasound
    • 8.5.1. Doppler Analysis
    • 8.5.2. Three D Four D Analysis
    • 8.5.3. Two D Analysis

9. Cancer Imaging System Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Cancer Imaging System Market, by Technology

  • 10.1. Artificial Intelligence
    • 10.1.1. Computer Aided Detection
    • 10.1.2. Computer Aided Diagnosis
    • 10.1.3. Workflow Management
  • 10.2. Contrast Imaging
    • 10.2.1. CT Contrast Agents
    • 10.2.2. MRI Contrast Agents
    • 10.2.3. Ultrasound Contrast Agents
  • 10.3. Hybrid Imaging
    • 10.3.1. PET CT Hybrid
    • 10.3.2. PET MRI Hybrid
    • 10.3.3. SPECT CT Hybrid
  • 10.4. Three D Visualization
    • 10.4.1. Max Intensity Projection
    • 10.4.2. Surface Rendering
    • 10.4.3. Volume Rendering

11. Cancer Imaging System Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Cancer Imaging System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Imaging System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Imaging System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. GE HealthCare Technologies, Inc.
    • 15.3.2. Siemens Healthineers AG
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Canon Medical Systems Corporation
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Hitachi, Ltd.
    • 15.3.7. Shimadzu Corporation
    • 15.3.8. Konica Minolta, Inc.
    • 15.3.9. Samsung Medison Co., Ltd.
    • 15.3.10. Hologic, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANCER IMAGING SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANCER IMAGING SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER IMAGING SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS CANC